Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52 Week Results
mediaposted on 2021-04-08, 09:08 authored by Adis Journals on behalf of, Yoshinori Umezawa, Akihiko Asahina, Shinichi Imafuku, Yayoi Tada, Shigetoshi Sano, Akimichi Morita, Shinya Sakurai, Naoki Hoshii, Nicola Tilt, Hidemi Nakagawa
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.